Comments
Loading...

IO Biotech Analyst Ratings

IOBTNASDAQ
Logo brought to you by Benzinga Data
$1.02
At close: May 15 EDT
$0.9900
-0.03-2.94%
Pre-Market: 9:16 AM EDT
Q1 2025 Earnings were released on Wed May 14th, before the market open
Consensus Rating1
Overweight
Highest Price Target1
$12.00
Lowest Price Target1
$6.00
Consensus Price Target1
$9.33

IO Biotech Analyst Ratings and Price Targets | NASDAQ:IOBT | Benzinga

IO Biotech Inc has a consensus price target of $9.33 based on the ratings of 3 analysts. The high is $12 issued by HC Wainwright & Co. on April 1, 2025. The low is $6 issued by Morgan Stanley on September 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 1, 2025, March 5, 2025, and November 12, 2024, respectively. With an average price target of $12 between HC Wainwright & Co., there's an implied 1112.12% upside for IO Biotech Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Morgan Stanley
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for IO Biotech

Buy NowGet Alert
04/01/2025Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
03/05/2025Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
11/12/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
11/06/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now506.06%Morgan Stanley
Matthew Harrison59%
$4 → $6MaintainsOverweightGet Alert
09/16/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
09/03/2024Buy Now910.1%Piper Sandler
Christopher Raymond53%
$10 → $10MaintainsOverweightGet Alert
09/03/2024Buy Now304.04%Morgan Stanley
Matthew Harrison59%
$7 → $4MaintainsOverweightGet Alert
09/03/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
08/14/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$12 → $12ReiteratesBuy → BuyGet Alert
05/15/2024Buy Now1112.12%HC Wainwright & Co.
Emily Bodnar37%
$8 → $12MaintainsBuyGet Alert
03/06/2024Buy Now708.08%HC Wainwright & Co.
Emily Bodnar37%
$8 → $8ReiteratesBuy → BuyGet Alert
09/28/2023Buy Now910.1%Piper Sandler
Christopher Raymond53%
→ $10Initiates → OverweightGet Alert
09/13/2023Buy Now708.08%HC Wainwright & Co.
Emily Bodnar37%
→ $8ReiteratesBuy → BuyGet Alert
08/15/2023Buy Now607.07%Morgan Stanley
Matthew Harrison59%
$11 → $7MaintainsOverweightGet Alert
08/11/2023Buy Now708.08%HC Wainwright & Co.
Emily Bodnar37%
$11 → $8ReiteratesBuy → BuyGet Alert
03/15/2023Buy Now910.1%HC Wainwright & Co.
Emily Bodnar37%
→ $10Reiterates → BuyGet Alert
01/24/2023Buy Now1011.11%Morgan Stanley
Matthew Harrison59%
$15 → $11MaintainsOverweightGet Alert
11/21/2022Buy Now910.1%HC Wainwright & Co.
Emily Bodnar37%
→ $10Initiates → BuyGet Alert

FAQ

Q

What is the target price for IO Biotech (IOBT) stock?

A

The latest price target for IO Biotech (NASDAQ:IOBT) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months (a possible 1112.12% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for IO Biotech (IOBT)?

A

The latest analyst rating for IO Biotech (NASDAQ:IOBT) was provided by HC Wainwright & Co., and IO Biotech reiterated their buy rating.

Q

When was the last upgrade for IO Biotech (IOBT)?

A

There is no last upgrade for IO Biotech

Q

When was the last downgrade for IO Biotech (IOBT)?

A

There is no last downgrade for IO Biotech.

Q

When is the next analyst rating going to be posted or updated for IO Biotech (IOBT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IO Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IO Biotech was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.

Q

Is the Analyst Rating IO Biotech (IOBT) correct?

A

While ratings are subjective and will change, the latest IO Biotech (IOBT) rating was a reiterated with a price target of $12.00 to $12.00. The current price IO Biotech (IOBT) is trading at is $0.99, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch